#China #Shanghai #Innovation #Argo Biopharma #siRNA

Argo Biopharma Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Argo Biopharma, a clinical-stage company specializing in small interfering RNA (siRNA) therapeutics, has earned a spot on Fast Company's prestigious list of the World's Most Innovative Companies for 2026. This accolade puts Argo Biopharma alongside industry giants like Google, Nvidia, Adidas, and Walmart, highlighting its significant role in revolutionizing healthcare through innovation.

Dr. Dongxu Shu, the co-founder and CEO of Argo Biopharma, expressed his gratitude for this recognition, stating, "We are honored to be recognized as one of the World's Most Innovative Companies of 2026. This acknowledgment underscores our dedication to developing breakthrough therapies designed to provide more treatment options and enhance outcomes for patients globally. We're focused on our potential functional cures and pioneering long-duration treatments."

Argo Biopharma is currently advancing a promising pipeline in multiple therapeutic areas. Notably, their candidate BW-20507, aimed at treating hepatitis B virus (HBV), has shown positive results in Phase I/IIa trials and is now progressing into Phase II, for which it has received Breakthrough Therapy Designation in China. This further emphasizes its potential as a functional cure.

In addition, the firm is making strides with BW-20805 for patients with hereditary angioedema (HAE), which is also in Phase II and has garnered Fast Track Designation from the U.S. FDA due to recent encouraging clinical data. Moreover, Argo Biopharma is strengthening collaborations in cardiovascular disease research, notably with Novartis, propelling multiple programs toward late-stage clinical development.

Fast Company's assessment of the World's Most Innovative Companies is an anticipated annual tradition, evaluating thousands of submissions from companies pushing the envelope across various sectors. This honoree list is compiled by the editorial team of Fast Company, who review these innovations to spotlight organizations that are not just adjusting to changes, but actively driving them.

Brendan Vaughan, editor-in-chief of Fast Company, remarked, "Companies we honor this year are redefining what leadership looks like in 2026. They are merging bold ideas with tangible impact and translating breakthrough innovation into real-world benefits, setting the standard for their industries and showcasing the power of sustained innovation."

Fast Company, the media brand that published this list, is dedicated to the essential intersection of business, innovation, and design, connecting influential leaders and thinkers on the future of global business.

As a biotechnology company in its clinical stage, Argo Biopharma aims to develop the next generation of RNAi therapeutics that provide improved treatment options for patients facing various health challenges. With a diverse and robust pipeline targeting cardiovascular diseases, viral infections, metabolic conditions, and rare diseases, Argo Biopharma demonstrates its commitment to addressing significant health issues. Currently, seven of its RNAi candidates are in clinical development, reflecting a strong dedication to advancing medical science.

For further details about Argo Biopharma and its innovative approaches, visit www.argobiopharma.com.